

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/537303  
JC17 Rec'd PCT/PTO 02 JUN 2005

Appl. No. : National Phase Entry of PCT/EP03/013655  
Applicant : MEISE et al  
Filed : Herewith  
TC/A.U. :  
Examiner :

Docket No. : 2923-703  
Customer No. : 6449  
Confirmation No. :

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


Sir:

In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed is a copy of the International Search Report in the corresponding international application. The relevance of the references is noted in the International Search Report. We understand that the references have been forwarded by the International Bureau, and are available to the Examiner, but if the Examiner needs copies of any of the references, the Examiner is requested to advise counsel accordingly.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

By



Robert B. Murray  
Attorney for Applicant  
Registration No. 22,980  
ROTHWELL, FIGG, ERNST & MANBECK  
1425 K. Street, Suite 800  
Washington, D.C. 20005  
Telephone: (202) 783-6040

RBM/cb

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Complete if Known</i>	
				Application Number	New Application <b>2923-703</b>
				Filing Date	Herewith
				First Named Inventor	MEISE et al
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	1	of	2	Attorney Docket Number	2923-703

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
	1.	WO	97/06262	A	Incyte Pharma Inc.	2/20/97	
	2.	WO	99/14340	A	Incyte Pharma Inc.	3/25/99	
Examiner Signature					Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Complete if Known</i>	
				Application Number	New Application <del>407536303</del>
				Filing Date	Herewith
				First Named Inventor	MEISE et al
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	2	of	2	Attorney Docket Number	2923-703

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
	3.	Kadambi et al., "Impaired ventricular relaxation resulting from cardiac-specific overexpression of a human prenylated protein tyrosine phosphatase", CIRCULATION, vol. 102, no. 18 Supplement, 31 October 2000, pg. II. 268.		
	4.	Hoit et al., "Restrictive cardiomyopathy in transgenic mice with cardiac-specific overexpression of a tyrosine phosphatase, PRL-3", CIRCULATION, vol. 104, no. 17 Supplement, 23 October 2001, pg. II.164		
Examiner Signature			Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.